Mohammad H Abu Arja1, Joseph R Stanek1, Andrés E Morales La Madrid2, Alvaro Lassaletta3, Ute Bartels4, Ibrahim Qaddoumi5, Jonathan L Finlay1, Diana S Osorio6. 1. The Department of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. 2. The Department of Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain. 3. The Pediatric Oncology, Hematology and Stem Cell Transplant Department, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. 4. The Department of Hematology Oncology, Hospital for Sick Children, Toronto, Canada. 5. Global Pediatric Medicine Department, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. The Department of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and The Ohio State University, 700 Children's Drive, Columbus, OH, 43205, USA. Diana.Osorio@nationwidechildrens.org.
Abstract
PURPOSE: The Latin American Brain Tumor Board (LATB) is a weekly teleconference connecting pediatric neuro-oncologists from referral centers in high-income countries with pediatric subspecialists from 20 Latin American countries since 2013. This survey explored the participants' experience utilizing this resource. METHODS: A cross-sectional electronic questionnaire was distributed to 159 participants through email and Cure4Kids. RESULTS: Ninety-five respondents (60%) from all the participating countries completed the survey. Sixty-one reported frequent-attendance (≥ 1 per month), 23 reported infrequent-attendance (< 1 per month), and 11 never participated. The most frequently reported attendance-barriers were the subspecialist's workload (64%), the timing of the teleconference (38%), and Internet connectivity problems (29%). Subspecialist's workload was more frequently reported as a barrier compared with other barriers, in both the frequent- and infrequent-attendance groups (p < 0.05), with the exception of the timing of the meeting in the infrequent-attendance group. More than 80% of attendees found the frequency and duration of the teleconference were sufficient. Utilizing Spanish as the primary language was reported to enhance the recommendations by 93% of the attendees. Moreover, 84% reported that the recommendations (almost) always fit the local circumstances. Furthermore, 99% of attendees found the teleconference provided a continuing medical education opportunity. Finally, 96% of attendees (almost) always found that the provided recommendations helped to improve the outcomes/quality of life of the patients. CONCLUSIONS: The LATB teleconference provided a valuable tool for the management of pediatric brain tumors in Latin America as it provided a feasible and easy to access continued medical education opportunity for the participants.
PURPOSE: The Latin American Brain Tumor Board (LATB) is a weekly teleconference connecting pediatric neuro-oncologists from referral centers in high-income countries with pediatric subspecialists from 20 Latin American countries since 2013. This survey explored the participants' experience utilizing this resource. METHODS: A cross-sectional electronic questionnaire was distributed to 159 participants through email and Cure4Kids. RESULTS: Ninety-five respondents (60%) from all the participating countries completed the survey. Sixty-one reported frequent-attendance (≥ 1 per month), 23 reported infrequent-attendance (< 1 per month), and 11 never participated. The most frequently reported attendance-barriers were the subspecialist's workload (64%), the timing of the teleconference (38%), and Internet connectivity problems (29%). Subspecialist's workload was more frequently reported as a barrier compared with other barriers, in both the frequent- and infrequent-attendance groups (p < 0.05), with the exception of the timing of the meeting in the infrequent-attendance group. More than 80% of attendees found the frequency and duration of the teleconference were sufficient. Utilizing Spanish as the primary language was reported to enhance the recommendations by 93% of the attendees. Moreover, 84% reported that the recommendations (almost) always fit the local circumstances. Furthermore, 99% of attendees found the teleconference provided a continuing medical education opportunity. Finally, 96% of attendees (almost) always found that the provided recommendations helped to improve the outcomes/quality of life of the patients. CONCLUSIONS: The LATB teleconference provided a valuable tool for the management of pediatric brain tumors in Latin America as it provided a feasible and easy to access continued medical education opportunity for the participants.
Entities:
Keywords:
Central nervous system tumors; Childhood brain tumors; Global oncology; Lower and middle income countries; Neuro-oncology; Telemedicine
Authors: Paula Aristizabal; Spencer Fuller; Rebeca Rivera-Gomez; Mario Ornelas; Laura Nuno; Carlos Rodriguez-Galindo; Raul Ribeiro; William Roberts Journal: Pediatr Blood Cancer Date: 2016-12-21 Impact factor: 3.167
Authors: Ibrahim Qaddoumi; Ibrahim Nawaiseh; Mustafa Mehyar; Bassem Razzouk; Barrett G Haik; Saamir Kharma; Imad Jaradat; Carlos Rodriguez-Galindo; Matthew W Wilson Journal: Pediatr Blood Cancer Date: 2008-08 Impact factor: 3.167
Authors: Matthew Christopher Davis; Dang D Can; Jonathan Pindrik; Brandon G Rocque; James M Johnston Journal: World Neurosurg Date: 2015-09-03 Impact factor: 2.104
Authors: Patrick D Hoek; Henk J Schers; Ewald M Bronkhorst; Kris C P Vissers; Jeroen G J Hasselaar Journal: BMC Med Date: 2017-06-19 Impact factor: 8.775
Authors: Mohammad H Abu-Arja; Nicolás Rojas Del Río; Andres Morales La Madrid; Alvaro Lassaletta; Scott L Coven; Rosa Moreno; Miguel Valero; Veronica Perez; Felipe Espinoza; Eduardo Fernandez; José Santander; Juan Tordecilla; Veronica Oyarce; Katherine Kopp; Ute Bartels; Ibrahim Qaddoumi; Jonathan L Finlay; Adrián Cáceres; Mauricio Reyes; Ximena Espinoza; Diana S Osorio Journal: JCO Glob Oncol Date: 2021-03
Authors: Lidia S van Huizen; Pieter U Dijkstra; Sjoukje van der Werf; Kees Ahaus; Jan Ln Roodenburg Journal: BMJ Open Date: 2021-12-09 Impact factor: 2.692